MorphoSys AG
XETRA:MOR
MorphoSys AG
Operating Income
MorphoSys AG
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
MorphoSys AG
XETRA:MOR
|
Operating Income
-€232.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
BioNTech SE
NASDAQ:BNTX
|
Operating Income
€908m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
CureVac NV
NASDAQ:CVAC
|
Operating Income
-€269.7m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
Immatics NV
NASDAQ:IMTX
|
Operating Income
-€101.7m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
Biotest AG
XETRA:BIO
|
Operating Income
€120.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
57%
|
CAGR 10-Years
8%
|
|
Formycon AG
XETRA:FYB
|
Operating Income
-€17.7m
|
CAGR 3-Years
-100%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
N/A
|
See Also
What is MorphoSys AG's Operating Income?
Operating Income
-232.9m
EUR
Based on the financial report for Dec 31, 2023, MorphoSys AG's Operating Income amounts to -232.9m EUR.
What is MorphoSys AG's Operating Income growth rate?
Operating Income CAGR 5Y
-42%
Over the last year, the Operating Income growth was -10%.